175 related articles for article (PubMed ID: 27175797)
1. Skp2 is associated with paclitaxel resistance in prostate cancer cells.
Yang Y; Lu Y; Wang L; Mizokami A; Keller ET; Zhang J; Fu J
Oncol Rep; 2016 Jul; 36(1):559-66. PubMed ID: 27175797
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
3. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
[TBL] [Abstract][Full Text] [Related]
4. CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer.
Li Y; Mizokami A; Izumi K; Narimoto K; Shima T; Zhang J; Dai J; Keller ET; Namiki M
Prostate; 2010 Jan; 70(1):48-60. PubMed ID: 19725034
[TBL] [Abstract][Full Text] [Related]
5. Skp2 and Slug Are Coexpressed in Aggressive Prostate Cancer and Inhibited by Neddylation Blockade.
Mickova A; Kharaishvili G; Kurfurstova D; Gachechiladze M; Kral M; Vacek O; Pokryvkova B; Mistrik M; Soucek K; Bouchal J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799604
[TBL] [Abstract][Full Text] [Related]
6. A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer.
Byun WS; Jin M; Yu J; Kim WK; Song J; Chung HJ; Jeong LS; Lee SK
Biochem Pharmacol; 2018 Dec; 158():84-94. PubMed ID: 30292755
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of Skp2 is correlated with p27-associated cell cycle arrest induced by phenylacetate in human prostate cancer cells.
Shibahara T; Onishi T; Franco OE; Arima K; Sugimura Y
Anticancer Res; 2005; 25(3B):1881-8. PubMed ID: 16158921
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of cytokeratin 18 is associated with paclitaxel‑resistance and tumor aggressiveness in prostate cancer.
Yin B; Zhang M; Zeng Y; Li Y; Zhang C; Getzenberg RH; Song Y
Int J Oncol; 2016 Apr; 48(4):1730-6. PubMed ID: 26892177
[TBL] [Abstract][Full Text] [Related]
9. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1.
Li X; Han X; Wei P; Yang J; Sun J
Cancer Biol Ther; 2020 May; 21(5):452-462. PubMed ID: 32089062
[TBL] [Abstract][Full Text] [Related]
11. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.
Liu Z; Zhu G; Getzenberg RH; Veltri RW
J Cell Biochem; 2015 Jul; 116(7):1341-9. PubMed ID: 25640606
[TBL] [Abstract][Full Text] [Related]
12. The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells.
Natsagdorj A; Izumi K; Hiratsuka K; Naito R; Kadomoto S; Iwamoto H; Yaegashi H; Shigehara K; Nakata H; Mizokami A
Anticancer Res; 2023 Jun; 43(6):2561-2569. PubMed ID: 37247914
[TBL] [Abstract][Full Text] [Related]
13. The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer.
Bochis OV; Irimie A; Pichler M; Berindan-Neagoe I
J Gastrointestin Liver Dis; 2015 Jun; 24(2):225-34. PubMed ID: 26114183
[TBL] [Abstract][Full Text] [Related]
14. PI3K/Akt signaling regulates p27(kip1) expression via Skp2 in PC3 and DU145 prostate cancer cells, but is not a major factor in p27(kip1) regulation in LNCaP and PC346 cells.
van Duijn PW; Trapman J
Prostate; 2006 May; 66(7):749-60. PubMed ID: 16425184
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomics and chemical library screens reveal a novel SCF
Malek E; Abdel-Malek MA; Jagannathan S; Vad N; Karns R; Jegga AG; Broyl A; van Duin M; Sonneveld P; Cottini F; Anderson KC; Driscoll JJ
Leukemia; 2017 Mar; 31(3):645-653. PubMed ID: 27677741
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines.
Machioka K; Izumi K; Kadono Y; Iwamoto H; Naito R; Makino T; Kadomoto S; Natsagdorj A; Keller ET; Zhang J; Mizokami A
Oncotarget; 2018 Mar; 9(22):16185-16196. PubMed ID: 29662635
[TBL] [Abstract][Full Text] [Related]
17. Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells.
Koga H; Harada M; Ohtsubo M; Shishido S; Kumemura H; Hanada S; Taniguchi E; Yamashita K; Kumashiro R; Ueno T; Sata M
Hepatology; 2003 May; 37(5):1086-96. PubMed ID: 12717389
[TBL] [Abstract][Full Text] [Related]
18. Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.
Singh S; Chitkara D; Mehrazin R; Behrman SW; Wake RW; Mahato RI
PLoS One; 2012; 7(6):e40021. PubMed ID: 22768203
[TBL] [Abstract][Full Text] [Related]
19. STAT1 represses Skp2 gene transcription to promote p27Kip1 stabilization in Ras-transformed cells.
Wang S; Raven JF; Koromilas AE
Mol Cancer Res; 2010 May; 8(5):798-805. PubMed ID: 20407011
[TBL] [Abstract][Full Text] [Related]
20. Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate.
Shim EH; Johnson L; Noh HL; Kim YJ; Sun H; Zeiss C; Zhang H
Cancer Res; 2003 Apr; 63(7):1583-8. PubMed ID: 12670908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
